Serum peptidome for cancer detection: Spinning biologic trash into diagnostic gold

Journal of Clinical Investigation

Volumn 116, Issue 1, 2006, Pages 26-30

  Liotta, Lance A ^a   Petricoin, Emanuel F ^a  

^a GEORGE MASON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CELL PROTEIN; PLASMA PROTEIN; SERUM PEPTIDOME; TUMOR MARKER; UNCLASSIFIED DRUG;

ADVANCED CANCER; BLADDER CANCER; BLOOD SAMPLING; BREAST CANCER; CANCER; CANCER DIAGNOSIS; DIAGNOSTIC VALUE; DISEASE MARKER; ENZYMATIC DEGRADATION; EX VIVO STUDY; HUMAN; IMMUNOASSAY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN DEGRADATION; REVIEW; SERUM;

BIOLOGICAL MARKERS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; PEPTIDE FRAGMENTS; PROTEOME; REFERENCE VALUES;

EID: 31044448275     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI27467     Document Type: Review

References (20)

1. Anderson, N.L., and Anderson, N.G. 2002. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics. 1:845-867.
2. Petricoin, E.F., Fishman, D.A., Conrads, T.P., Veenstra, T.D., and Liotta, L.A. 2004. Lessons from Kitty Hawk: from feasibility to routine clinical use for the field of proteomic pattern diagnostics. Proteomics. 4:2357-2360.
3. Skates, S.J., et al. 2004. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J. Clin. Oncol. 22:4059-4066.
4. Petricoin, E.F., et al. 2002. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 359:572-577.
5. Adam, B.L., et al. 2002. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 62:3609-3614.
6. Li, J., Zhang, Z., Rosenzweig, J., Wang, Y.Y., and Chan, D.W. 2002. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 48:1296-1304.
7. Villanueva, J., et al. 2004. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal. Chem. 76:1560-1570.
8. Hingorani, S.R., et al. 2003. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 4:437-450.
9. Petricoin, E.F., 3rd, et al. 2002. Serum proteomic patterns for detection of prostate cancer. J. Natl. Cancer Inst. 94:1576-1578.
10. Stone, J.H., et al. 2005. Wegener's Granulomatosis Etanercept Trial Research Group. A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis. Arthritis Rheum. 52:902-910.
11. Liotta, L.A., Ferrari, M., and Petricoin, E. 2003. Clinical proteomics: written in blood. Nature. 425:905.
12. Tirumalai, R.S., et al. 2003. Characterization of the low molecular weight human serum proteome. Mol. Cell. Proteomics. 2:1096-1103.
13. Diamandis, E.P. 2003. Point: proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin. Chem. 49:1272-1275.
14. Sorace, J.M., and Zhan, M. 2003. A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics. 4:24.
15. Zhang, Z., et al. 2004. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 64:5882-5890.
16. Lowenthal, M.S., et al. 2005. Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin. Chem. 51:1933-1945.
17. Liotta, L.A., et al. 2005. Importance of communication between producers and consumers of publicly available experimental data. J. Natl. Cancer Inst. 97:310-314.
18. Villanueva, J., et al. 2006. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 116:271-284. doi:10.1172/JCI26022.
19. Zhou, M., et al. 2004. An investigation into the human serum "interactome". Electrophoresis. 25:1289-1298.
20. Lopez, M.F., et al. 2005. High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. Clin. Chem. 51:1946-1954.